PubMed=2848260; DOI=10.1073/pnas.85.23.9302
Heldin N.-E., Gustavsson B., Claesson-Welsh L., Hammacher A., Mark J., Heldin C.-H., Westermark B.
Aberrant expression of receptors for platelet-derived growth factor in an anaplastic thyroid carcinoma cell line.
Proc. Natl. Acad. Sci. U.S.A. 85:9302-9306(1988)
PubMed=14522906
Frasca F., Vella V., Aloisi A., Mandarino A., Mazzon E., Vigneri R., Vigneri P.
p73 tumor-suppressor activity is impaired in human thyroid cancer.
Cancer Res. 63:5829-5837(2003)
PubMed=17465858; DOI=10.1089/thy.2006.0246
Lee J.J., Foukakis T., Hashemi J., Grimelius L., Heldin N.-E., Wallin G., Rudduck C., Lui W.-O., Hoog A., Larsson C.
Molecular cytogenetic profiles of novel and established human anaplastic thyroid carcinoma models.
Thyroid 17:289-301(2007)
PubMed=17725429; DOI=10.1089/thy.2007.0097
Meireles A.M., Preto A., Rocha A.S., Rebocho A.P., Maximo V., Pereira-Castro I., Moreira S., Feijao T., Botelho T., Marques R., Trovisco V., Cirnes L., Alves C., Velho S., Soares P., Sobrinho-Simoes M.
Molecular and genotypic characterization of human thyroid follicular cell carcinoma-derived cell lines.
Thyroid 17:707-715(2007)
PubMed=18713817; DOI=10.1210/jc.2008-1102
Schweppe R.E., Klopper J.P., Korch C., Pugazhenthi U., Benezra M., Knauf J.A., Fagin J.A., Marlow L.A., Copland J.A., Smallridge R.C., Haugen B.R.
Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.
J. Clin. Endocrinol. Metab. 93:4331-4341(2008)
PubMed=19087340; DOI=10.1186/1471-2407-8-371
Ribeiro F.R., Meireles A.M., Rocha A.S., Teixeira M.R.
Conventional and molecular cytogenetics of human non-medullary thyroid carcinoma: characterization of eight cell line models and review of the literature on clinical samples.
BMC Cancer 8:371-371(2008)
PubMed=21868764; DOI=10.1158/1078-0432.CCR-11-0690
Zhao M., Sano D., Pickering C.R., Jasser S.A., Henderson Y.C., Clayman G.L., Sturgis E.M., Ow T.J., Lotan R., Carey T.E., Sacks P.G., Grandis J.R., Sidransky D., Heldin N.-E., Myers J.N.
Assembly and initial characterization of a panel of 85 genomically validated cell lines from diverse head and neck tumor sites.
Clin. Cancer Res. 17:7248-7264(2011)
PubMed=23833040; DOI=10.1210/jc.2013-2383
Landa I., Ganly I., Chan T.A., Mitsutake N., Matsuse M., Ibrahimpasic T., Ghossein R.A., Fagin J.A.
Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease.
J. Clin. Endocrinol. Metab. 98:E1562-E1566(2013)
PubMed=25365311; DOI=10.1210/jc.2014-2359
Garg M., Okamoto R., Nagata Y., Kanojia D., Venkatesan S., Anand M.T., Braunstein G.D., Said J.W., Doan N.B., Ho Q., Akagi T., Gery S., Liu L.-Z., Tan K.T., Chang W.J., Yang H., Ogawa S., Koeffler H.P.
Establishment and characterization of novel human primary and metastatic anaplastic thyroid cancer cell lines and their genomic evolution over a year as a primagraft.
J. Clin. Endocrinol. Metab. 100:725-735(2015)
PubMed=26680454; DOI=10.1186/s12885-015-1955-9
Kasaian K., Wiseman S.M., Walker B.A., Schein J.E., Zhao Y., Hirst M., Moore R.A., Mungall A.J., Marra M.A., Jones S.J.M.
The genomic and transcriptomic landscape of anaplastic thyroid cancer: implications for therapy.
BMC Cancer 15:984-984(2015)
PubMed=30737244; DOI=10.1158/1078-0432.CCR-18-2953
Landa I., Pozdeyev N., Korch C., Marlow L.A., Smallridge R.C., Copland J.A., Henderson Y.C., Lai S.Y., Clayman G.L., Onoda N., Tan A.C., Garcia-Rendueles M.E.R., Knauf J.A., Haugen B.R., Fagin J.A., Schweppe R.E.
Comprehensive genetic characterization of human thyroid cancer cell lines: a validated panel for preclinical studies.
Clin. Cancer Res. 25:3141-3151(2019)
PubMed=31368081; DOI=10.1007/s12020-019-02009-5
Pinto A.T., Pojo M., Simoes-Pereira J., Roque R., Saramago A., Roque L., Martins C., Andre S., Cabecadas J., Leite V., Cavaco B.M.
Establishment and characterization of a new patient-derived anaplastic thyroid cancer cell line (C3948), obtained through fine-needle aspiration cytology.
Endocrine 66:288-300(2019)